Review of Osteosarcoma and Current Management

Osteosarcoma is the most common primary malignancy of bone in children and young adults. This tumor has a very heterogeneous genetic profile and lacks any consistent unifying event that leads to the pathogenesis of osteosarcoma. In this review, some of the important genetic events involved in osteosarcoma will be highlighted. Additionally, the clinical diagnosis of osteosarcoma will be discussed, as well as contemporary chemotherapeutic and surgical management of this tumor. Finally, the review will discuss some of the novel approaches to treating this disease.

[1]  M. M. Copeland,et al.  Classification of bone tumors. , 1951, Bulletin of the Hospital for Joint Diseases.

[2]  J. Qin,et al.  Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma , 2011, Oncogene.

[3]  J. Ippolito,et al.  Results of 20 consecutive patients treated with the Repiphysis expandable prosthesis for primary malignant bone , 2015, SpringerPlus.

[4]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Zhaoming Ye,et al.  Prognostic Significance of Serum Alkaline Phosphatase Level in Osteosarcoma: A Meta-Analysis of Published Data , 2015, BioMed research international.

[6]  L. Mirabello,et al.  Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.

[7]  R. Grimer,et al.  Osteosarcoma of the pelvis. , 2016, The bone & joint journal.

[8]  Dongqi Li,et al.  A comparative study between limb-salvage and amputation for treating osteosarcoma , 2016, Journal of bone oncology.

[9]  M. Fehlings,et al.  Osteosarcoma of the spine: prognostic variables for local recurrence and overall survival, a multicenter ambispective study. , 2016, Journal of neurosurgery. Spine.

[10]  S. Altekruse,et al.  Outcomes for children and adolescents with cancer: challenges for the twenty-first century. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Simon,et al.  Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study. , 1994, The Journal of bone and joint surgery. American volume.

[12]  M. Bui,et al.  Osteosarcoma in Pediatric Patients and Young Adults: A Single Institution Retrospective Review of Presentation, Therapy, and Outcome , 2014, Sarcoma.

[13]  S. Keir,et al.  Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.

[14]  T. He,et al.  IGFBP5 domains exert distinct inhibitory effects on the tumorigenicity and metastasis of human osteosarcoma. , 2013, Cancer letters.

[15]  J. Nevins,et al.  The Rb/E2F pathway and cancer. , 2001, Human molecular genetics.

[16]  M. Sporn,et al.  Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. , 1983, The Journal of biological chemistry.

[17]  R. Grimer,et al.  Endoprosthetic reconstruction for the treatment of musculoskeletal tumors of the appendicular skeleton and pelvis. , 2008, The Journal of bone and joint surgery. American volume.

[18]  J. Wunder,et al.  Prognosis of Radiation-induced Bone Sarcoma is Similar to Primary Osteosarcoma , 2006, Clinical orthopaedics and related research.

[19]  P. Terrier,et al.  Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Hansen,et al.  Osteosarcoma in Paget's Disease of Bone , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  R. von Eisenhart-Rothe,et al.  Long-term functional outcome and quality of life following rotationplasty for treatment of malignant tumors , 2015, BMC Musculoskeletal Disorders.

[22]  Jiangdong Ni,et al.  Molecular mechanisms of chemoresistance in osteosarcoma (Review) , 2014, Oncology letters.

[23]  S. Scully,et al.  Clinical Outcome of 38 Patients With Juxtacortical Osteosarcoma , 2000, Clinical orthopaedics and related research.

[24]  J. W. van der Eijken,et al.  Osteosarcoma over the age of forty. , 2003, European journal of cancer.

[25]  John H. Healey,et al.  Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: A report from the Children’s Oncology Group , 2008 .

[26]  D. Louis,et al.  CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. , 1998, The American journal of pathology.

[27]  M. Manfrini,et al.  Are Complications Associated With the Repiphysis® Expandable Distal Femoral Prosthesis Acceptable for Its Continued Use? , 2015, Clinical orthopaedics and related research.

[28]  R. W. Miller.  Contrasting epidemiology of childhood osteosarcoma, Ewing's tumor, and rhabdomyosarcoma. , 1981, National Cancer Institute monograph.

[29]  G. Draper,et al.  Incidence of second primary tumours among childhood cancer survivors. , 1987, British Journal of Cancer.

[30]  Brian M. Trotta,et al.  Benign Osteoid-Producing Bone Lesions: Update on Imaging and Treatment , 2013, Seminars in Musculoskeletal Radiology.

[31]  J. Shuster,et al.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. , 1986, The New England journal of medicine.

[32]  I. Andrulis,et al.  Expression of insulin‐like growth factor receptor, IGF‐1, and IGF‐2 in primary and metastatic osteosarcoma , 1998, Journal of surgical oncology.

[33]  J. Benítez,et al.  Effect of ABCB1 and ABCC3 Polymorphisms on Osteosarcoma Survival after Chemotherapy: A Pharmacogenetic Study , 2011, PloS one.

[34]  B. Czerniak,et al.  Bone cancers , 1995, Cancer.

[35]  S. Bielack,et al.  Periosteal osteosarcoma--a European review of outcome. , 2005, European journal of cancer.

[36]  G. Letson,et al.  Orthopedic surgery options for the treatment of primary osteosarcoma. , 2008, Cancer control : journal of the Moffitt Cancer Center.

[37]  D. Mankoff,et al.  Tumor metabolic rates in sarcoma using FDG PET. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  M. Manfrini,et al.  Resurfaced allograft-prosthetic composite for proximal tibial reconstruction in children: intermediate-term results of an original technique. , 2015, The Journal of bone and joint surgery. American volume.

[39]  M. Ladanyi,et al.  p53 and MDM2 alterations in osteosarcomas , 1997, Cancer.

[40]  G. Bacci,et al.  Primary bone osteosarcoma in the pediatric age: state of the art. , 2006, Cancer treatment reviews.

[41]  E. Kleinerman,et al.  Increased Fas Expression Reduces the Metastatic Potential of Human Osteosarcoma Cells , 2004, Clinical Cancer Research.

[42]  E. Kleinerman,et al.  Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. , 2001, Cancer research.

[43]  M. Gebhardt,et al.  Expression of transforming growth factor‐beta (TGF‐β) receptors, TGF‐β1 and TGF‐β2 production and autocrine growth control in osteosarcoma cells , 1994 .

[44]  M. Semik,et al.  Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Samardziski,et al.  Parosteal osteosarcoma. , 2009, Bratislavske lekarske listy.

[46]  M. Gebhardt,et al.  Expression of transforming growth factor‐β (TGF‐β) isoforms in osteosarcomas , 1997 .

[47]  I. Dos Santos Silva,et al.  Sex differences in the risks of hormone-dependent cancers. , 1993, American journal of epidemiology.

[48]  M. Sydes,et al.  Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  A. Mavrogenis,et al.  Palliative treatments for advanced osteosarcoma. , 2012, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[50]  M. Coenen,et al.  A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment , 2015, Clinical Cancer Research.

[51]  H J Mankin,et al.  Long-Term Results of Allograft Replacement in the Management of Bone Tumors , 1996, Clinical orthopaedics and related research.

[52]  P. Rossen,et al.  Pazopanib in metastatic osteosarcoma: Significant clinical response in three consecutive patients , 2014, Acta oncologica.

[53]  F. O’Sullivan,et al.  Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[54]  J. Fraumeni.  Stature and malignant tumors of bone in childhood and adolescence , 1967, Cancer.

[55]  Piero Picci,et al.  Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy , 2006, Cancer.

[56]  P. Casali,et al.  Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. , 2015, The Lancet. Oncology.

[57]  K. S. Hall,et al.  EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  S. Tokluoğlu,et al.  Outcomes of Adolescent and Adult Patients with Lung Metastatic Osteosarcoma and Comparison of Synchronous and Metachronous Lung Metastatic Groups , 2016, PloS one.

[59]  David M. Thomas,et al.  Genome-wide Association Study Identifies Two Susceptibility Loci for Osteosarcoma , 2013, Nature Genetics.

[60]  W. Winkelmann,et al.  Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  G. Moriceau,et al.  Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. , 2010, Cancer research.

[62]  C. Bonaïti‐pellié,et al.  Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  T. He,et al.  The Current and Future Therapies for Human Osteosarcoma. , 2013, Current cancer therapy reviews.

[64]  D. Heymann,et al.  Targeted therapies for bone sarcomas. , 2013, BoneKEy reports.

[65]  R. Grimer,et al.  Characteristics, diagnosis and treatment of bone and soft tissue sarcomas. , 2007, British journal of hospital medicine.

[66]  P. Desai,et al.  Sarcoma in association with bone infarcts. Report of five cases. , 1996, Archives of pathology & laboratory medicine.

[67]  M. Manfrini,et al.  Long-term Results in Children With Massive Bone Osteoarticular Allografts of the Knee for High-grade Osteosarcoma , 2010, Journal of pediatric orthopedics.

[68]  K. Ishizaki,et al.  Mutation spectrum of the retinoblastoma gene in osteosarcomas. , 1994, Cancer research.

[69]  A. Stewart,et al.  Osteosarcoma, Chondrosarcoma, and Ewing's Sarcoma: National Cancer Data Base Report , 2007, Clinical orthopaedics and related research.

[70]  P. Meltzer,et al.  Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  M. Simon,et al.  Limb salvage for osteosarcoma in the 1980s. , 1991, Clinical orthopaedics and related research.

[72]  G. Rosen,et al.  Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy , 1982, Cancer.

[73]  S. Bielack,et al.  Current strategies of chemotherapy in osteosarcoma , 2006, International Orthopaedics.

[74]  S. Ferrari,et al.  High grade osteosarcoma of the extremities with lung metastases at presentation: Treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions , 2008, Journal of surgical oncology.

[75]  E. Haura,et al.  Src kinases as therapeutic targets for cancer , 2009, Nature Reviews Clinical Oncology.

[76]  I. Hickson,et al.  DNA helicase deficiencies associated with cancer predisposition and premature ageing disorders. , 2001, Human molecular genetics.

[77]  N. Jaffe.  Recent advances in the chemotherapy of metastatic osteogenic sarcoma , 1972, Cancer.

[78]  E. Pignotti,et al.  Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy The Rizzoli experience in 52 patients , 2006, Acta orthopaedica.

[79]  D. Zurakowski,et al.  Pathologic Fracture in Osteosarcoma: Prognostic Importance and Treatment Implications , 2002, The Journal of bone and joint surgery. American volume.

[80]  E. Kleinerman,et al.  Fas expression inversely correlates with metastatic potential in osteosarcoma cells. , 2002, Oncology reports.

[81]  T. Delaney,et al.  Radiotherapy for local control of osteosarcoma. , 2003, International journal of radiation oncology, biology, physics.

[82]  S. Hirschfeld,et al.  Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. , 1994, Cancer research.

[83]  P. Casali,et al.  A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[84]  Toshifumi Ozaki,et al.  Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  B. Fuchs,et al.  Worse prognosis of osteosarcoma patients expressing IGF-1 on a tissue microarray. , 2014, Anticancer research.

[86]  Yusuke Nakamura,et al.  Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma , 1989, Nature.

[87]  S. Ferrari,et al.  An update on chemotherapy for osteosarcoma , 2015, Expert opinion on pharmacotherapy.

[88]  R. Gorlick,et al.  Inhibition of Src Phosphorylation Alters Metastatic Potential of Osteosarcoma In vitro but not In vivo , 2009, Clinical Cancer Research.

[89]  J. Mayerson,et al.  Osteosarcoma: A Meta-Analysis and Review of the Literature. , 2015, American journal of orthopedics.

[90]  B. Sartorius,et al.  Pre-treatment serum lactate dehydrogenase and alkaline phosphatase as predictors of metastases in extremity osteosarcoma , 2015, Journal of bone oncology.

[91]  L. Ritacco,et al.  Oncologic and clinical outcomes in pelvic primary bone sarcomas treated with limb salvage surgery , 2015, MUSCULOSKELETAL SURGERY.

[92]  R. Grimer,et al.  Surgical options for children with osteosarcoma. , 2005, The Lancet. Oncology.

[93]  Mike Wilson,et al.  IGF‐1 receptor contributes to the malignant phenotype in human and canine osteosarcoma , 2004, Journal of cellular biochemistry.

[94]  Chao-Yang Wan,et al.  The efficacy of high-dose versus moderate-dose chemotherapy in treating osteosarcoma: a systematic review and meta-analysis. , 2015, International journal of clinical and experimental medicine.

[95]  David M. Thomas,et al.  Translational biology of osteosarcoma , 2014, Nature Reviews Cancer.

[96]  Y. Hua,et al.  Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: a meta-analysis , 2014, Journal of Cancer Research and Clinical Oncology.

[97]  Lisa Mirabello,et al.  International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons , 2009, International journal of cancer.

[98]  C. Franzius,et al.  Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  M. Campanacci.  Bone and Soft Tissue Tumors: Clinical Features, Imaging, Pathology and Treatment , 1999 .

[100]  G. Farfalli,et al.  Survival, Recurrence, and Function After Epiphyseal Preservation and Allograft Reconstruction in Osteosarcoma of the Knee , 2015, Clinical orthopaedics and related research.

[101]  S. Ferrari,et al.  Advances in emerging drugs for osteosarcoma , 2015, Expert opinion on emerging drugs.

[102]  H. Mankin,et al.  The Hazards of the Biopsy, Revisited. For the Members of the Musculoskeletal Tumor Society* , 1996, The Journal of bone and joint surgery. American volume.

[103]  H. Gelderblom,et al.  Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? , 2011, European journal of cancer.

[104]  M. G. Fox,et al.  Osteosarcoma: Review of the Various Types with Emphasis on Recent Advancements in Imaging , 2013, Seminars in Musculoskeletal Radiology.

[105]  R. Grimer,et al.  Very long-term outcomes after endoprosthetic replacement for malignant tumours of bone. , 2016, The bone & joint journal.

[106]  Y. Qian,et al.  The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle , 1991, Cell.

[107]  M. Hansen,et al.  Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. , 1998, American journal of human genetics.

[108]  H. Kimura,et al.  Prognosis of Osteosarcoma With Pulmonary Metastases at Initial Presentation Is Not Dismal , 1998, Clinical orthopaedics and related research.

[109]  R. Romagnoli,et al.  Malignant tumors of the osteogenic matrix. , 1998, European Journal of Radiology.

[110]  M. Clayer.  Many faces of osteosarcoma on plain radiographs , 2015, ANZ journal of surgery.

[111]  T. Murray.  Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. , 1998, Survey of ophthalmology.

[112]  P. Houghton,et al.  Phase I study of everolimus in pediatric patients with refractory solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  Y. Qi,et al.  MicroRNA-133a Inhibits Osteosarcoma Cells Proliferation and Invasion via Targeting IGF-1R , 2016, Cellular Physiology and Biochemistry.

[114]  L. Helman,et al.  Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. , 2005, Cancer research.

[115]  C. Prives,et al.  Transcriptional regulation by p53. , 2010, Cold Spring Harbor perspectives in biology.

[116]  M. Gebhardt,et al.  Expression of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas: TGF-beta3 is related to disease progression. , 1997, Cancer.

[117]  G. Letson,et al.  Adult Soft Tissue Sarcoma Local Recurrence After Adjuvant Treatment Without Resection of Core Needle Biopsy Tract , 2013, Clinical orthopaedics and related research.

[118]  L. Strong,et al.  Localization of a novel tumor suppressor locus on human chromosome 3q important in osteosarcoma tumorigenesis. , 1997, Cancer research.

[119]  M. Gebhardt,et al.  Expression of transforming growth factor-beta (TGF-beta) receptors, TGF-beta 1 and TGF-beta 2 production and autocrine growth control in osteosarcoma cells. , 1994, International journal of cancer.

[120]  E. Pignotti,et al.  Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. , 2002, The Journal of bone and joint surgery. British volume.

[121]  J. Debus,et al.  Radiotherapy in the Treatment of Primary Osteosarcoma – a Single Center Experience , 2010, Tumori.

[122]  I. Hickson,et al.  Defending genome integrity during DNA replication: a proposed role for RecQ family helicases , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[123]  W. Winkelmann,et al.  Osteosarcoma: the COSS experience. , 2009, Cancer treatment and research.

[124]  S. Kaste,et al.  Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis , 1999, Cancer.

[125]  B. V. van Royen,et al.  Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature , 2011, Clinical & Experimental Metastasis.

[126]  M. Tucker,et al.  Sarcomas in hereditary retinoblastoma , 2012, Clinical Sarcoma Research.

[127]  I. Hickson,et al.  RecQ family helicases: roles in cancer and aging. , 2000, Current opinion in genetics & development.

[128]  D. Barkauskas,et al.  Poor Survival for Osteosarcoma of the Pelvis: A Report from the Children’s Oncology Group , 2012, Clinical orthopaedics and related research.

[129]  N. Nagelkerke,et al.  Non‐ocular cancer in patients with hereditary retinoblastoma and their relatives , 1988, International journal of cancer.

[130]  Li Ding,et al.  Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.

[131]  C. Hattinger,et al.  Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma , 2015, Expert opinion on drug metabolism & toxicology.

[132]  Liliana Vásquez,et al.  Analysis of Prognostic Factors in High-Grade Osteosarcoma of the Extremities in Children: A 15-Year Single-Institution Experience , 2016, Front. Oncol..

[133]  S. Ferrari,et al.  Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  S. Lipshultz,et al.  Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group , 2016, Pediatric blood & cancer.

[135]  G. Siegal,et al.  Osteosarcoma: anatomic and histologic variants. , 2006, American journal of clinical pathology.

[136]  H J Mankin,et al.  Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. , 2005, The Journal of bone and joint surgery. American volume.

[137]  David M. Thomas,et al.  A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. , 2015, Cancer discovery.

[138]  J. Mayerson,et al.  Pelvic Resection: Current Concepts , 2014, The Journal of the American Academy of Orthopaedic Surgeons.